Deepa G. Manwani
<p>Dr. Manwani is a pediatric hematologist who leads the sickle cell team at CHAM. The team offers treatment and support for young children and teens with sickle cell disease and their families, including weekly support groups and an annual Sickle Cell Awareness Day event focused on new research and strategies for living with this disease.</p>
<p>Benign hematology, anemia, sickle cell disease, thalassemia, hemophilia, bleeding disorders, thrombosis, neutropenia, thrombocytopenia, ITP, erythrocytosis, thrombocytosis, leukocytosis.</p>
<p>Sickle Cell Disease: Novel therapies, Role of adhesion and neutrophils, Alloimmunization, Transition to adult care, Fetal hemoglobin induction, Gut Microbiome, Pain, Chronic Pain, Quality Improvement.</p>
<p>Deepa Manwani, MD, is Director, Pediatric Hematology at Children?s Hospital at Montefiore, as well as a Professor in the Department of Pediatrics at Albert Einstein College of Medicine. Dr. Manwani?s clinical focus is on benign hematology, anemia, sickle cell disease, thalassemia, hemophilia, bleeding disorders, thrombosis, neutropenia, thrombocytopenia, ITP, erythrocytosis and leukocytosis. </p><p>Dr. Manwani graduated from B.J. Medical College, Poona University, India, in 1991, earning her Doctor of Medicine. She became a Research Assistant at the Children?s Hospital Oakland in 1991 before beginning an internship in Pediatrics at NSUH-Cornell University Med Center in 1993. Following her internship, Dr. Manwani completed a residency in Pediatrics at the same institution. In 1996, she began a fellowship in Pediatrics Hematology/Oncology at Mount Sinai School of Medicine in New York. </p><p>Dr. Manwani?s research focuses on fetal hemoglobin activating agents, adhesive cellular interactions in vaso-occlusion in sickle cell disease (SCD) and contribution of neutrophils to SCD pathophysiology. She completed the R01 funded Phase 1 study of IVIG in the treatment of SCD vaso-occlusive crises and is currently leading the R01 funded Phase II study. Dr. Manwani is currently participating in studies aimed at increased adherence to hydroxyurea and improved transition to adult care. She is also collaborating with investigators at Case Western Reserve University on an NHLBI R01 funded study to standardize monitoring of cellular adhesion in SCD patients using a novel microfluidic assay. Her contributions have been recognized by the Sickle Cell Thalassemia Patient Network of New York in the form of the Distinguished Service Award in March 2015. Dr. Manwani?s studies have been published nationally in various reviewed journals and books. </p><p>Dr. Manwani has received many awards, including Castle Connolly Top Doctor in 2016, New York Magazine Best Doctor and New York Metro Area?s Top Doctors in 2017. </p>